Psychiatry research. Neuroimaging
August 1, 2026
Kengo Yonezawa, Shinichiro Nakajima, Shuhei Shibukawa et al.
Ketamine may alleviate treatment-resistant depression (TRD) primarily through glutamatergic modulation, with downstream dopaminergic activation. Iron plays an important role in monoaminergic metabolism, that is also implicated in the pathophysiology of TRD. Both Quantitative Susceptibility Mapping (QSM) and Effective Transverse Relaxation Rate (R2*) mapping can determine the extent of iron...
Current Pharmaceutical Design
July 31, 2026
Prachi Tayal, Rina Das, M.U. Khan et al.
BACKGROUND: Major depressive disorder (MDD) is one of the leading causes of disability globally, and conventional monoaminergic antidepressants often have a slow onset and limited efficacy. About onethird of patients suffer from treatment-resistant depression (TRD), which emphasizes the urgent need for alternative therapies. This review aims to systematically evaluate the available data about...
Frontiers in Psychiatry
July 30, 2026
Muhammad Abbas, Bruno Kallas, Max Garris
This is a case report of a 52 year old female with ECT-refractory bipolar depression who was treated with esketamine nasal spray, leading to a noticeable improvement in her depressive symptoms. She experienced a relapse after a reduction in her maintenance treatment in conjunction with psychosocial stressors, but improved once again after returning to her induction regimen. She tolerated the...
Annals of Clinical Psychiatry
July 29, 2026
Neha Ather, Mashal Zahid, Mohammad Hassan et al.
Background Depression remains a leading cause of disability and suicide worldwide, with treatment-resistant depression (TRD) affecting nearly 30% of individuals diagnosed with major depressive disorder. Esketamine nasal spray (NS) and quetiapine extended-release (XR) are both approved as adjunctive therapies for TRD; however, direct head-to-head comparisons are limited. Method A systematic...
J Clin Psychopharmacol
July 28, 2026
Hepatic Safety of Ketamine and Esketamine for Treatment-Resistant Depression: A Real-World Cohort Study.
npj Mental Health Research
July 27, 2026
Jennifer Swainson, P. Grewal, S. Polard et al.
This scoping review maps literature for use of ketamine or esketamine with psychotherapy for depression or depressive symptoms. Forty-seven studies were identified including 4/47 (9%) randomized controlled trials, 4/47 (9%) open label trials, 27/47 (57%) observational or retrospective studies, and 12/47 (26%) individual case reports. Studies were categorized as Ketamine/Esketamine Combined with...
McMaster University Medical Journal
July 26, 2026
Annie Xiong, Sebastian Kolde, Paul Links
Background: Pharmacologic treatment options for borderline personality disorder (BPD) remain limited, and no medication has received regulatory approval for its treatment. Given the high rates of comorbid depression and suicidal ideation in BPD, there is growing interest in novel therapeutic approaches. Ketamine has been approved for treatment-resistant depression and acute suicidality, raising...
Pharmacology, biochemistry, and behavior
July 26, 2026
Peng Zhang, Mengyu Wu, Keke Zhang et al.
Esketamine has been approved for the treatment of treatment-resistant depression. However, there is an unmet clinical need to extend the duration of esketamine's action to reduce the high recurrence rate after drug withdrawal and the potential side effects of repeated esketamine use. Here, we found that increasing extracellular signal-regulated kinase (ERK) activity by pharmacologically...
J Affect Disord
July 23, 2026
Rapid clinical and EEG microstate changes 24 h after intranasal esketamine in major depressive disorder with suicidal ideation: a prospective paired study.
Curr Neuropharmacol
July 22, 2026
Esketamine in Treatment-Resistant Depression: Clinical and Translational Perspectives.